Centocor sells UK plant to Trinity Biotech
This article was originally published in Clinica
Centocor, the US biotech company, has sold its UK diagnostic test factory to Trinity Biotech for $5.5 million. The plant, in Guildford, Surrey, develops and manufactures infectious disease tests in microtitre EIA (enzyme immunoassay) plate format. These include tests for rubella, herpes, syphilis and a recently developed test for Chagas disease. The business had a turnover of $3.2 million in 1996.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.